Carl Zeiss Meditec (CZMWY) Stock Price, News & Analysis

Company Overview

Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, such as ametropia (refraction), cataracts, glaucoma, and renital disorders. This segment also provides devices for general ophthalmological examination and care, including slit lamps, refractometers, tonometers, optical coherence tomography devices, and fundus cameras; and devices for functional diagnostics (perimeters), as well as digital products for storage, evaluation, and sharing of clinical data. In addition, this segment offers surgical ophthalmology products comprising surgical microscopes, biometers, phacoemulsification, and vitrectomy devices; intraocular lenses for cataract patients; and systems and consumables for laser eye surgery. The Microsurgery segment provides products and solutions for invasive surgical treatments; and solutions in the area of ear, nose and throat, plastic and reconstructive, neuro, dental, and spinal surgeries. It serves physicians in various fields and hospitals. The company was founded in 1846 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG is a subsidiary of Carl Zeiss AG.

Key Stats

• Today's Range: $65.51 to $68.66
• 50-Day Range: $53.34 to $75.74
• 52-Week Range: $46.13 to $108.74
• Volume: 659 shs
• Average Volume: 5,990 shs
• Market Capitalization: N/A
• P/E Ratio: 73.20
• Dividend Yield: 0.45%
• Price Target: N/A
• Consensus Rating: Hold

Carl Zeiss Meditec Stock Analysis - MarketRank™

Carl Zeiss Meditec scored higher than 17% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Carl Zeiss Meditec.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Carl Zeiss Meditec is 73.20, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 21.98.

Price to Earnings Ratio vs. Sector

The P/E ratio of Carl Zeiss Meditec is 73.20, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 22.77.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Carl Zeiss Meditec has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Carl Zeiss Meditec has recently decreased by 50.00%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Carl Zeiss Meditec pays a meaningful dividend of 1.36%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Carl Zeiss Meditec does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Carl Zeiss Meditec is 32.64%. This payout ratio is at a healthy, sustainable level, below 75%.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Carl Zeiss Meditec has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Carl Zeiss Meditec has recently decreased by 50.00%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: N/A

News Sentiment

Carl Zeiss Meditec has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Carl Zeiss Meditec insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 0.10% of the stock of Carl Zeiss Meditec is held by institutions.

CZMWY Stock Analysis - Frequently Asked Questions

How have CZMWY shares performed this year?

Carl Zeiss Meditec's stock was trading at $47.50 on January 1st, 2025. Since then, CZMWY stock has increased by 41.8% and is now trading at $67.34.
View the best growth stocks for 2025 here.

How do I buy shares of Carl Zeiss Meditec?

Shares of CZMWY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Record date for 4/15 Dividend: 3/28/2025
• Ex-Dividend for 4/15 Dividend: 3/28/2025
• Dividend Payable: 4/15/2025
• Today: 5/03/2025
• Next Earnings (Estimated): 5/13/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Medical Instruments & Supplies
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:CZMWY
• CIK: N/A
• Web: www.zeiss.com
• Phone: 493641220115
• Fax: N/A
• Employees: 4,823
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: 73.20
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A